Exaggerating or falsifying Clinical trials is considered FDA fraud

Falsifying or exaggerating clinical trial results be deemed FDA fraud :

The FDA relies on trial data to verify the safety and efficacy of drugs. If any party in the trial process misrepresents, omits, or falsifies the data, such FDA fraud can create far-reaching damage to future users of the drug. Healthcare employers and healthcare whistleblowers are on the lookout for falsification of trial data that increase revenue dollars for the provider.